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Abstract 95 
Background: Daily use of high potency cannabis has been reported to carry a high 96 
risk for psychotic disorder. However, the evidence is mixed on whether any pattern of 97 
cannabis use is associated with a particular symptomatology in first episode psychosis 98 
(FEP) patients. 99 
Method: We analysed data from 901 patients and 1235 controls recruited across six 100 
countries, as part of the European Network of National Schizophrenia Networks 101 
Studying Gene-Environment Interactions (EU-GEI) study. We used item response 102 
modelling to estimate two bifactor models, which included general and specific 103 
dimensions of psychotic symptoms in patients and psychotic experiences in controls. 104 
The associations between these dimensions and cannabis use were evaluated using 105 
linear mixed effects models analyses. 106 
Results: In patients, there was a linear relationship between the positive symptom 107 
dimension and the extent of lifetime exposure to cannabis, with daily users of high 108 
potency cannabis having the highest score (B=0.35; 95%CI 0.14 to 0.56). Moreover, 109 
negative symptoms were more common among patients who never used cannabis 110 
compared with those with any pattern of use (B=-0.22; 95%CI -0.37 to -0.07). In 111 
controls, psychotic experiences were associated with current use of cannabis but not 112 
with the extent of lifetime use. Neither patients nor controls presented differences in 113 
depressive dimension related to cannabis use. 114 
Conclusions: Our findings provide the first large scale evidence that first episode 115 
psychotic patients with a history of daily use of high potency cannabis present with 116 
more positive and less negative symptoms than those who never used cannabis or 117 
used low potency types. 118 
 119 
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 123 
Introduction 124 
There is compelling evidence suggesting that cannabis use is associated with 125 
psychotic disorders (Marconi et al., 2016). However, it is unclear whether cannabis 126 
use is a ‘modifier’ factor for psychotic disorders, which affects symptom presentation. 127 
The existence of a pattern of psychotic symptomatology particularly associated with 128 
cannabis has been described in several case series (Walter Bromberg, 1934, Talbott 129 
and Teague, 1969, Spencer, 1971, Bernhardson and Gunne, 1972, Chopra and 130 
Smith, 1974). Nevertheless, case and cohort studies have found mixed results as to 131 
whether (Negrete et al., 1986, Peralta and Cuesta, 1992, Bersani et al., 2002, Green 132 
et al., 2004, Grech et al., 2005, Addington and Addington, 2007, Foti et al., 2010, 133 
Ringen et al., 2016, Seddon et al., 2016)  or not (Thornicroft et al., 1992, Stirling et al., 134 
2005, Dubertret et al., 2006, Boydell et al., 2007, van Dijk et al., 2012, Tosato et al., 135 
2013, Barrowclough et al., 2015) psychotic patients using cannabis present with more 136 
positive symptoms than those not using cannabis. Moreover, there is mixed evidence 137 
of any relationship between cannabis use and negative symptoms in psychosis. Some 138 
reports suggest fewer negative symptoms in psychotic patients that use cannabis 139 
(Peralta and Cuesta, 1992, Bersani et al., 2002, Green et al., 2004), which is 140 
consistent with having enough social skills to obtain the substance (Murray et al., 141 
2017). However, this association has not been confirmed in other studies (Grech et 142 
al., 2005, Seddon et al., 2016) and others even reported a positive association (Ringen 143 
et al., 2016). 144 
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These inconsistencies might be explained by differences in study design and methods. 145 
For example, only a few findings were based on first episode psychosis (FEP) patients 146 
(Grech et al., 2005, Addington and Addington, 2007, Tosato et al., 2013, Seddon et 147 
al., 2016), which minimize selection and recall bias, and the confounding effect of 148 
antipsychotic drugs on symptoms. In addition, a metanalysis of longitudinal studies 149 
concluded that most results lacked sufficient power to detect an effect of cannabis on 150 
symptoms, or inadequately controlled for potential confounders (Zammit et al., 2008). 151 
Furthermore, although a few studies included information on frequency of use, all 152 
failed to obtain detailed information on the lifetime pattern of cannabis use, especially 153 
on the type and strength of cannabis used. Of note, potent cannabis varieties, with 154 
high concentrations of Delta-9-Tetrahydrocannabinol (〉9-THC), have been 155 
associated with the most harm to mental health (Di Forti et al., 2015, Freeman et al., 156 
2018) and, in recent years, these potent types have become more available worldwide 157 
(ElSohly et al., 2016, Potter et al., 2018, Freeman et al., 2019). Finally, no studies 158 
have used factor analysis of observed symptoms to evaluate to what extent cannabis 159 
use is a factor influencing the clinical heterogeneity of psychosis. 160 
On the other hand, in the general population there are consistent findings regarding 161 
the association between cannabis use and psychotic experiences (Ragazzi et al., 162 
2018). However, most studies had limited geographical coverage and the examined 163 
population was scarcely representative of the population at risk of psychosis (Ragazzi 164 
et al., 2018). 165 
In this study, we set out to clarify the association between detailed patterns of cannabis 166 
use and transdiagnostic symptom dimensions in a large multinational FEP sample. In 167 
addition, we examine the association between detailed patterns of cannabis use and 168 
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subclinical symptom dimensions in a large sample of controls representative of the 169 
population at risk in each catchment area. 170 
Specifically, we sought to test the hypotheses that: (1) positive psychotic symptoms 171 
are more common among FEP patients with more frequent lifetime use of cannabis 172 
and greater exposure to use of high potency varieties; (2) positive psychotic 173 
experiences are more common in population controls with a recent use of cannabis, 174 
who would be more resilient to the long-term effects of cannabis; (3) negative 175 
symptoms are more common among those patients who have never used cannabis. 176 
 177 
Methods 178 
Study design and participants 179 
This analysis is based on the incidence and case-control study work package of the 180 
EUropean network of national schizophrenia networks studying Gene-Environment 181 
Interactions (EU-GEI). 182 
FEP individuals were identified between 2010 and 2015 across six countries to 183 
examine incidence rates of schizophrenia and other psychotic disorders (Jongsma et 184 
al., 2018), and symptomatology at psychosis onset (Quattrone et al., 2019). For 185 
examining risk factors, we sought to perform an extensive assessment on 186 
approximately 1,000 FEP patients and 1,000 population-based controls during the 187 
same time period. 188 
Patients were included in the case-control study if they met the following criteria during 189 
the recruitment period: (a) aged between 18 and 64 years; (b) presentation with a 190 
clinical diagnosis for an untreated FEP, even if longstanding [International Statistical 191 
Classification of Diseases and Related Health Problems, Tenth Revision (ICD-10) 192 
codes F20-F33]; (c) resident within the catchment area. Exclusion criteria were: (a) 193 
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previous contact with psychiatric services for psychosis; (b) psychotic symptoms 194 
originating from an identified organic condition; and (c) transient psychotic symptoms 195 
resulting from acute intoxication (ICD-10: F1x.5).  196 
The recruitment of controls followed a mixture of random and quota sampling methods, 197 
in order to achieve the best possible representativeness in age, sex, and ethnicity of 198 
the population living in each catchment area. The identification process varied by site 199 
and was based on locally available sampling frames, including mostly the use of lists 200 
of all postal addresses and general practitioners’ lists from randomly selected 201 
surgeries. When these resources were not fully available, internet and newspapers 202 
advertising were used to fill quotas. Exclusion criteria for controls were: (a) diagnosis 203 
of a psychotic disorder; (b) ever having been treated for psychotic symptoms. 204 
We analysed data from eleven catchment areas, including urban and less urban 205 
populations (i.e. Southeast London, Cambridgeshire and Peterborough (England); 206 
central Amsterdam, Gouda and Voorhout (the Netherlands); Bologna municipality, city 207 
of Palermo (Italy); Paris [Val-de-Marne], Puy-de-Dôme (France); Madrid [Vallecas], 208 
Barcelona (Spain); and Ribeirão Preto (Brazil). Further information on the case-control 209 
sample and the recruitment strategies is included in the supplementary material. 210 
Measures 211 
Data on age, sex, and ethnicity were collected using a modified version of the Medical 212 
Research Council Sociodemographic Schedule (Mallett, 1997). The OPerational 213 
CRITeria (OPCRIT) system (McGuffin et al., 1991) was used by centrally trained 214 
investigators, whose reliability was assessed before and throughout the study (k=0.7), 215 
to assess psychopathology in the first four weeks after the onset and generate 216 
research-based diagnoses based on different diagnostic classification systems. The 217 
Community Assessment of Psychic Experiences (CAPE) (Stefanis et al., 2002) was 218 
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administered to controls to self-report their psychotic experiences. The reliability of the 219 
CAPE is good for all the languages spoken in the countries forming part of the EU-220 
GEI study (http://cape42.homestead.com). 221 
A modified version of the Cannabis Experience Questionnaire (CEQEU-GEI) (Di Forti et 222 
al., 2009) was used by investigators to collect extensive information on the patterns of 223 
use of cannabis and other drugs. We used six measures of cannabis use 224 
(Supplementary Table S2), including a variable measuring specific patterns of 225 
cannabis exposure by combining the frequency of use with the potency of cannabis. 226 
As illustrated in the supplementary material, the cannabis potency variable was based 227 
on the data published in the European Monitoring Centre for Drugs and Drug Addiction 228 
(EMCDDA) (European Monitoring Centre for Drugs and Drug Addiction, 2013, Di Forti 229 
et al., 2019). 230 
We selected confounders based on their possible association with cannabis use 231 
and/or symptom dimensions. These included: sex; age; ethnicity; use of stimulants, 232 
hallucinogens, ketamine, cocaine, crack, and novel psychoactive substances; current 233 
use of cigarettes (smoking 10 cigarettes or more per day=1), and current use of alcohol 234 
(drinking 10 alcohol units or more per week=1).  235 
Statistical analysis 236 
Dimensions of psychotic symptoms in patients and psychotic experiences in 237 
controls 238 
Data from OPCRIT and CAPE were analysed using multidimensional item response 239 
modelling in Mplus, version 7.4 (Muthén and Muthén, 2012), to estimate two bifactor 240 
models, based on the associations among observer ratings of psychotic symptoms in 241 
patients and self-ratings of psychotic experiences in controls. This methodology is 242 
described in full in our EU-GEI paper on symptom dimensions in FEP patients 243 
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(Quattrone et al., 2019), and it was likewise applied to psychotic experiences in 244 
population controls. Briefly, CAPE items were dichotomized as 0 ‘absent’ or 1 245 
‘present’. In order to ensure sufficient covariance coverage for item response 246 
modelling, we used items with a valid frequency of ‘present’ ≥10% in our sample, and 247 
we excluded items with low correlation values (<.3) based on the examination of the 248 
item correlation matrix. As in the previous analysis in patients, the bifactor solution 249 
was compared with other solutions (i.e., unidimensional, multidimensional, and 250 
hierarchical models) using Log-Likelihood (LL), Akaike Information Criterion (AIC), 251 
Bayesian Information Criterion (BIC), and Sample-size Adjusted BIC (SABIC) as 252 
model fit statistics. Path diagrams that illustrate these models are presented in 253 
Supplementary Figure S1. Reliability and strength indices such as McDonald’s omega 254 
(の) (Rodriguez et al., 2016), omega hierarchical (のH) (Rodriguez et al., 2016), and 255 
index H (Hancock and Mueller, 2001), were computed to determine: 1) the proportion 256 
of common variance accounted by general and specific symptom dimensions; 2) the 257 
proportion of reliable variance accounted by the general dimension not unduly affected 258 
by the specific dimensions; 3) the proportion of reliable variance accounted for by each 259 
specific dimension not unduly affected by the general and all the other specific 260 
dimensions; 4) the overall reliability and replicability of the bifactor construct of 261 
psychosis-like experiences. Finally, we generated factor scores for one general 262 
psychotic experience dimension and three specific dimensions of positive, negative, 263 
and depressive psychotic experiences. 264 
For patients, we used the previously generated factor scores for one general 265 
psychosis dimension and five specific dimensions of positive, negative, disorganised, 266 
manic, and depressive symptoms (Quattrone et al., 2019).  267 
Symptom dimensions and cannabis use 268 
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We evaluated the relationship between psychotic symptom dimensions in patients, or 269 
psychotic experience dimensions in controls, and cannabis use using linear mixed 270 
effects models in STATA14 (StataCorp, 2015). We specifically modelled symptom 271 
dimension scores as a function of each of the six measures of cannabis use. We then 272 
evaluated the combined effect of frequency of use and potency of cannabis. To 273 
account for the non-independence of symptom profiles of subjects assessed within 274 
the same country (for example, due to cultural similarities), and for the potential within-275 
site correlation (for example, due to context factors), we fitted a three-level mixed 276 
model, where the random effect encompassed two levels of random intercepts: one 277 
due to the countries, and another due to the sites within the countries. Finally, we used 278 
the Benjamini-Hochberg (B-H) procedure to reduce the false discovery rate, which we 279 
set at 5%.  280 
 281 
Results 282 
Sample characteristics 283 
We analysed data from 901 FEP patients and 1,235 controls. The main socio-284 
demographic characteristics and history of substance misuse of patients and controls 285 
are presented in Supplementary Table S1. Supplementary Tables S3 and S5 show 286 
the sample prevalence of psychotic experiences in controls and of psychotic 287 
symptoms in patients. 288 
Bifactor model of psychotic experiences in controls 289 
Supplementary Table S4 shows that, as in our previous analysis of the OPCRIT items 290 
(Quattrone et al., 2019), the bifactor model provided the best fit for the CAPE items, 291 
as illustrated by AIC, BIC and SABIC substantially lower compared with competing 292 
models. This solution explained 60% of the unique variance. In addition, Figure 1 293 
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shows that, within the bifactor model, the explained variance was due to individual 294 
differences mostly on the general psychotic experience dimension. This is illustrated 295 
by the relative omega coefficient, which, for example, showed that 85% of the reliable 296 
variance was due to the general dimension when partitioning out the variability in 297 
scores due to the specific dimensions. Moreover, factor loadings of moderate to high 298 
magnitude were observed for most items on the general psychotic experience 299 
dimension, whereas factor loadings of a smaller magnitude were observed for the 300 
specific dimensions (Figure 1). Consistently, the index H, which is a measure of the 301 
construct reliability and replicability across studies (Hancock and Mueller, 2001), was 302 
very high for the general dimension (0.92), moderate for positive (0.78) and negative 303 
(0.71) dimensions and lower for the depressive dimension (0.41).  304 
 305 
Symptom dimensions in patients by pattern of cannabis use  306 
Models’ results are presented in Table 1.1 which shows that: 307 
1) There were no differences in the distribution of positive symptoms according to early 308 
age at first use (=<15 years old), nor, after B-H correction, according to ever or current 309 
use of cannabis. However, positive symptoms were more common among patients 310 
who spent more than 20 euros per week on cannabis (B=0.3; 95%CI 0.11 to 0.48; 311 
p=0.001). 312 
2) Fewer negative symptoms were observed among those patients who used 313 
cannabis at least once compared with those who never tried (B=-0.22; 95%CI -0.37 to 314 
-0.07; p=0.004). Early age at first use and current use of cannabis was not associated 315 
with negative symptomatology. 316 
3) Manic symptoms were more frequent among patients who had ever used cannabis 317 
(B=0.22; 95%CI 0.08 to 0.36; p=0.002). 318 
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4) There were no differences in the distribution of the scores on the depressive, 319 
disorganization and general psychosis dimensions according to any measure of 320 
cannabis use. 321 
 322 
 323 
Psychotic experience dimensions in population controls by patterns of 324 
cannabis use 325 
Models’ results are presented in Table 1.2, which shows that: 326 
1) There were no differences in the distribution of positive psychotic experiences 327 
according to ever use of cannabis or early age at first use (=<15 years old). However, 328 
positive psychotic experiences were more commonly reported by subjects who 329 
currently used cannabis (B=0.33; 95%CI 0.15 to 0.51; p<0.001) and who spent more 330 
than 20 euros per week on cannabis (B=0.39; 95%CI 0.09 to 0.69; p=0.011).  331 
2) There were no differences in the distribution of the depressive and negative 332 
experiences in population controls according to cannabis use. 333 
 334 
Symptom dimensions by frequency of use and potency of cannabis 335 
The independent effects of frequency of use and potency of cannabis is reported in 336 
Supplementary Tables S6.1 and S6.2, and Supplementary Figure S2, showing that, 337 
only in patients, positive symptoms were more common in those who used cannabis 338 
on a daily basis and exposed to high potency varieties  339 
Testing the combined ‘type-frequency’ variable in patients, we found evidence of a 340 
linear relationship between the positive symptom dimension and the extent of 341 
exposure to cannabis, with daily users of high potency cannabis showing the highest 342 
score (B=0.35; 95%CI 0.14 to 0.56; p=0.001). Therefore, we introduced a contrast 343 
operator and plotted the exposure-response relationship for positive symptoms 344 
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(Figure 2), by comparing the predictive margins of the adjusted mean of each group 345 
against the grand adjusted mean of all groups. Figure 2 shows that the adjusted mean 346 
for daily users of high potency cannabis was 0.2 units greater than the grand adjusted 347 
mean. Moreover, the adjusted means for the groups who never or rarely used 348 
cannabis were respectively 0.16 or 0.18 units lower than the grand adjusted mean. 349 
A negative relationship between the negative symptom dimension score and patterns 350 
of cannabis use was also observed in patients. Figure 3 shows that patients with 351 
psychosis who never used cannabis had more negative symptoms either compared 352 
with the grand adjusted mean or with any pattern of cannabis use. 353 
 354 
Discussion 355 
Principal findings 356 
This is the first multinational study analysing data on the potency of the cannabis used 357 
by FEP patients to investigate a dose effect relationship between cannabis use and 358 
dimensions of symptoms, and also its effect on dimensions of psychotic experiences 359 
in population controls. We provide the first evidence that: 1) in patients, a positive 360 
correlation exists between the extent of premorbid cannabis use and the score on the 361 
positive symptom dimension, with daily users of high potency cannabis showing the 362 
most positive symptoms at FEP; 2) psychotic experiences in non-clinical populations 363 
are associated with current use of cannabis but are independent of the extent of 364 
lifetime exposure to cannabis; 3) negative symptoms at FEP are more common in 365 
patients who have never tried cannabis; 4) depressive symptoms are independent of 366 
any pattern of use of cannabis.  367 
Limitations 368 
Our findings must be considered in the context of two main limitations. First, individual 369 
data on patterns of cannabis use are not validated with biological samples. However, 370 
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biological tests are not considered the gold standard method for such a validation 371 
(Large et al., 2012) and would not allow one to ascertain the extent of cannabis use 372 
over the years (Taylor et al., 2017). Moreover, studies combining self-report and 373 
laboratory data support the reliability of subjects in reporting the type of cannabis they 374 
use (Wolford et al., 1999, Freeman et al., 2014). Second, we did not take into account 375 
the cannabidiol (CBD) contribution to the potency variable, as official data on its 376 
content in the different cannabis varieties were not available in most study sites; CBD 377 
might counterbalance 〉9-THC effects and minimise both psychotic experiences 378 
(Schubart et al., 2011) and symptoms (McGuire et al., 2018).  379 
Comparison with previous research 380 
We extend previous research on cannabis and psychotic symptoms to a multinational 381 
sample confirming the association between cannabis use and positive symptoms of  382 
FEP (Ringen et al., 2016, Seddon et al., 2016). Our results are in line with Schoeler et 383 
al. (2016), who carefully scrutinised the literature on the effect of continuation of 384 
cannabis use after FEP, concluding that this would be associated with a more severe 385 
positive symptomatology (Schoeler et al., 2016). That said, any comparison with 386 
previous research is limited by the lack of information on frequency and potency in all 387 
the previous studies along with subjects’ exposure to more potent varieties of cannabis 388 
in recent years (Potter et al., 2018). In this respect, we firstly provide some evidence 389 
that cannabis affects positive symptoms in a dose response manner, further 390 
supporting the converging epidemiological and experimental evidence that the use of 391 
cannabis with high content of 〉9-THC has a more detrimental effect than other 392 
varieties (Di Forti et al., 2009, Morrison et al., 2009, Freeman et al., 2018). 393 
We also report evidence in a multinational FEP sample of an association between 394 
lifetime cannabis use and fewer negative symptoms, the latter often considered as a 395 
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marker of greater neurodevelopmental impairment in psychotic subjects. Two opposite 396 
interpretations should be discussed.  397 
First, some authors have suggested that people with a psychotic disorder might use 398 
cannabis as an attempt to self-medicate negative symptoms, and thus the observed 399 
reduction in negative symptomatology would be an epiphenomenon due to the 400 
cannabis intake itself (Peralta and Cuesta, 1992).  401 
Second, psychotic disorders may be characterized by less neurodevelopmental 402 
features when associated with cannabis use (Ruiz-Veguilla et al., 2012, Ferraro et al., 403 
2013, Murray et al., 2017, Ferraro et al., 2019), hence FEP patients who do not initiate 404 
to use cannabis would have more negative symptoms.  405 
The lack of a dose dependency in our study appears to speak against the first and in 406 
favour of the second possibility, as the difference holds between those who never 407 
obtained cannabis and those who may have used it only once. Moreover, negative 408 
symptoms would reduce the social and instrumental skills that were necessary to 409 
obtain illegally cannabis and sustain its use in all the countries included in the study, 410 
except Holland.  411 
Last, we report that the cumulative exposure to cannabis does not impact on psychotic 412 
experiences in controls. One could of course argue that the largest proportion of 413 
subjects with the harmful pattern of cannabis use were patients. However, further 414 
research is needed to look into plausible mechanisms of resilience to the 415 
psychotogenic effect of cannabis as observed in our controls, who report psychotic 416 
experiences if current users but do not seem to accumulate a risk over life time 417 
cannabis use and develop psychotic disorders.  Indeed, future studies should aim to: 418 
1) investigate if and how genetic factors, plausibly regulating the endocannabinoid and 419 
dopamine systems, pose a small subset of cannabis users at high risk of developing 420 
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a psychotic disorders with particular symptomatology; 2) clarify over the course of the 421 
disorder whether or not differences in symptomatology between current and former 422 
cannabis users may be related to residual cannabis effects. 423 
Implications 424 
The novelty of our study is based on our examination of data on lifetime frequency of 425 
cannabis use and on the type of the cannabis used; high potency types are increasing 426 
worldwide. For instance, a recent potency study revealed that in London, the high 427 
potency type of cannabis called skunk has now taken up 96% of the street market 428 
(Potter et al., 2018). The EMCDDA has described a European cannabis market 429 
characterised by potent varieties (European Monitoring Centre for Drugs and Drug 430 
Addiction, 2013) Iike those present in Amsterdam coffee shops that can reach up to 431 
39% of THC. Indeed, as daily use, and use of high potency cannabis, have been 432 
associated both with greatest risk to develop psychotic disorders and to high rates of 433 
psychotic disorders across Europe (Di Forti et al., 2019), here we show that in FEP 434 
patients daily use of high potency cannabis drives a high score on the positive 435 
symptom dimension. Further research should aim to determine biological mechanisms 436 
underlying how cannabis impacts on different clinical manifestations of psychosis. 437 
Meanwhile, translating current findings into clinical practice, symptom dimension 438 
scores can be used to stratify patients and develop secondary prevention schemes for 439 
cannabis-associated psychosis.  440 
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Figure 1. Bifactor model of psychotic experiences in controls 
 
 
() Observed variables (No. of CAPE items); () Unobserved variables (latent factors); () standardized item loading estimation onto latent factors; G, general 
psychosis-like factor; Specific psychotic experiences factors: DEP, Depression; NEG, Negative; POS, Positive. Reliability and strenght estimates: H=construct 
reliability index; の= McDonald omega; のH=hierarchical omega; の/のH= Relative omega.  
Explanatory note: McDonald‘s の is an estimate of the proportion of the common variance accounted by general and specific symptom dimensions.(Rodriguez 
et al., 2016). Relative omega (の/のh) is the amount of reliable variance explained in the observed scores attributable to a) the general factor independently from 
the specific symptom dimensions, and 2) each specific symptom dimension independently from the general factor. 
H is an index of the quality of the measurement model based on the set of CAPE items for each dimension.(Hancock and Mueller, 2001) Indices can range 
from 0 to 1, with values closer to 1 indicating a better construct reliability and replicability across studies. 
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Figure 2. Positive symptom dimension in cases by patterns of cannabis use. 
 
Figure 2 shows the contrasts of the positive symptom dimension predicted mean of each group of 
patterns of use of cannabis against the predicted grand mean of all groups (represented by the red 
line). The positive value for the contrast of the daily use of high potency cannabis indicates more positive 
symptomatology in this group. On the other hand, negative values for the contrasts of the first two 
groups indicates less positive symptomatology when there is less exposure to cannabis. These 
differences are statistically significant, as indicated by 95% confidence intervals that do not overlap with 
zero. The model was a random intercept model which allowed symptoms to vary across countries and 
sites within countries, but it assumed that frequency of use and type of cannabis had an individual fixed 
effect. Values were adjusted for age, sex, ethnicity, diagnosis, and use of other recreational/illicit 
substances. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. Negative symptom dimension in cases by patterns of cannabis use. 
 
Figure 3 shows the contrasts of the negative symptom dimension predicted mean of each group of 
patterns of use of cannabis against the grand adjusted predicted mean (represented by the red line). 
Subjects who had never used cannabis presented with more negative symptoms compared to the whole 
sample. The model was a random intercept model which allowed symptoms to vary across countries 
and sites within countries, but it assumed that frequency of use and type of cannabis had an individual 
fixed effect. 
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effect. Values were adjusted for age, sex, ethnicity, diagnosis, and use of other recreational/illicit 
substances. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. Negative symptom dimension in cases by patterns of cannabis use. 
 
Figure 3 shows the contrasts of the negative symptom dimension predicted mean of each group of 
patterns of use of cannabis against the grand adjusted predicted mean (represented by the red line). 
Subjects who had never used cannabis presented with more negative symptoms compared to the whole 
sample. The model was a random intercept model which allowed symptoms to vary across countries 
and sites within countries, but it assumed that frequency of use and type of cannabis had an individual 
fixed effect. 
 
 
 
 
Table 1.1 Symptom dimensions in FEP patients by measures of cannabis usea 
Symptom dimension Ever used cannabis 
B (95% CI) 
Current use of 
cannabis 
B (95% CI) 
Age at first use of 
cannabis 
B (95% CI) 
Money used for 
cannabis 
B (95% CI) 
Positive 0.16* 
(0 to 0.31) 
0.21* 
(0.04 to 0.37) 
0.05 
(-0.13 to 0.22) 
0.3** 
(0.11 to 0.48) 
Negative -0.22** 
(-0.37 to -0.07) 
-0.09 
(-0.26 to 0.07) 
0.07 
(-0.09 to 0.22) 
0.07 
(-0.12 to 0.25) 
Depressive -0.08 
(-0.24 to 0.08) 
-0.08 
(-0.22 to 0.06) 
-0.09 
(-0.23 to 0.05) 
-0.11 
(-0.29 to 0.06) 
Disorganization -0.01 
(-0.24 to 0.03) 
0.01 
(-0.05 to 0.26) 
0.11 
(-0.06 to 0.28) 
0.1 
(-0.17 to 0.19) 
Manic 0.22** 
(0.08 to 0.36) 
0.12 
(-0.02 to 0.27) 
-0.09 
(-0.25 to 0.07) 
0.05 
(-0.11 to 0.22) 
General factor 0.05 
(-0.06 to 0.17) 
0.02 
(-0.1 to 0.14) 
-0.06 
(-0.09 to 0.22) 
0.03 
(-0.11 to 0.17) 
aAll models were adjusted for age, sex, ethnicity, use of other recreational/illicit substances, and 
diagnosis. Models were random-intercept models that included two random effects to allow 
symptomatology to vary across countries and across sites within countries but assumed that individual-
level exposure to cannabis had a fixed effect across the entire sample. 
Significance: * p < 0.05, ** p < 0.01, *** p < 0.001; associations that survived after Benjamini-Hochberg 
correction are showed in bold. 
 
 
Table 1.2 Psychotic experience dimensions in controls by cannabis usea 
Psychotic experience 
dimension 
Ever used 
cannabis 
B (95% CI) 
Current use of 
cannabis 
B (95% CI) 
Age at first use 
of cannabis 
B (95% CI) 
Money used for 
cannabis 
B (95% CI) 
Positive 0.05 
(-0.06 to 0.17) 
0.33*** 
(0.15 to 0.51) 
0.08 
(-0.11 to 0.25) 
0.39* 
(0.09 to 0.69) 
Negative  0.11 
(-0.01 to 0.24) 
0.16 
(-0.03 to 0.36) 
-0.11 
(-0.29 to 0.07) 
-0.12 
(-0.2 to 0.44) 
Depressive 0.09 
(-0.03 to 0.21) 
0.01 
(-0.19 to 0.20) 
-0.02 
(-0.21 to 0.16) 
-0.02 
(-0.3 to 0.35) 
General factor 0.04 
(-0.08 to 0.17) 
0.13 
(-0.07 to 0.33) 
0.08 
(-0.11 to 0.22) 
0.15 
(-0.18 to 0.48) 
aAll models were adjusted for age, sex, ethnicity, and use of other recreational/illicit substances. Models 
were random-intercept models that included two random effects to allow symptomatology to vary across 
countries and across sites within countries but assumed that individual-level exposure to cannabis had 
a fixed effect across the entire sample. 
Significance: * p < 0.05, ** p < 0.01, *** p < 0.001; associations that survived after Benjamini-Hochberg 
correction are showed in bold. 
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Supplementary Table S1. Socio-demographic characteristics and history of substance misuse 
of the analysed sample 
 FEP 
N=901 
Controls 
N=1235 
Age (mean; SD) 30.8 (10.5) 36.1 (13.3) 
Sex (male %; N) 61.9 (558) 47 (581) 
 
Self-reported Ethnicity   
White (%; N) 59.05 (532) 75.22 (929) 
Black 18.65 (168) 9.55 (118) 
Mixed 11.54 (104) 9.15 (113) 
Asian 3.55 (32) 2.67 (33) 
North African 4.66 (42) 1.86 (23) 
Others 2.55 (23) 1.54 (19) 
 
Ever used cannabis   
Yes (%;N) 64.93 (585) 46.48 (574) 
Missing 1.44 (13) 1.05 (13) 
   
Current use of cannabis    
Yes (%;N) 21.64 (195) 10.61 (131) 
Missing 1.78 (16) 1.05 (13) 
   
Age at first use of cannabis   
Never Used (%; N) 33.63 (303) 52.47 (648) 
<=15 year old 27.75 (250) 13.52 (167) 
     16 year old and older 35.74 (322) 32.96 (407) 
Missing 2.89 (26) 1.05 (13) 
   
Money used for cannabis (weekly)   
From 0 to 20 euro 76.47 (689) 92.3 (1,140) 
More than 20 euro 16.1 (145) 3.16 (39) 
Missing 7.44 (67) 4.53 (56) 
   
Lifetime frequency of use   
     Never use 56.83 (512) 52.47 (648) 
     Less than daily 11.54 (104) 39.68 (490) 
     Daily 28.86 (260) 6.72 (83) 
     Missing 2.77 (25) 1.13 (14) 
   
Type of cannabis   
Never used 33.63 (303) 55.57 (648) 
Less than 10% THC 26.64 (240) 23.89 (295) 
More than 10% THC 32.63 (294) 18.06 (223) 
Missing 7.1 (64) 5.59 (69) 
   
Current tobacco use   
Supplement Click here to access/download;Other Supplementary
Material;Final_supplementary_Psych_Med.docx
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
>10 cigarettes x day (%;N) 28.71 (262) 10.85 (134) 
Missing 3.77 (34) 1.94 (24) 
   
Current use of other drugs   
Stimulants (%;N) 
   Missing 
8.62 (82) 
1.6 (15) 
4.53 (56) 
  1.05 (13) 
Hallucinogens 
   Missing 
5.23 (49) 
1.92 (18) 
2.02 (25) 
1.21 (15) 
Ketamine 
   Missing 
2.13 (20) 
1.92 (18) 
1.05 (13) 
1.21(15) 
Novel Psychoactive Substances 
   Missing 
1.39 (13) 
1.71 (16) 
0.65 (8) 
1.05 (13) 
Crack 
      Missing 
2.67 (25) 
    1.6 (15) 
2 (0.16) 
    1.05 (13) 
Cocaine 
     Missing 
14.94 (140) 
    1.81 (17) 
5.83 (72) 
     1.13 (14) 
   
Current alcohol overuse   
Drinks =>10 units per week (%;N) 
      Missing 
10.88 (98) 
   11.4(103) 
12.47 (154) 
    3.24(40) 
   
Diagnosis   
Schizophrenia (%;N) 13.2 (282)  
Schizoaffective disorders 17.84 (381)  
Bipolar Disorders 2.48 (53)  
Psychotic Depression 1.92 (41)  
Unspecified Psychosis 6.74 (144)  
   
 
Supplementary table S2. Cannabis measures in the EU-GEI study 
 
Lifetime cannabis use 0=never used 1=Yes  
Currently using 
cannabis 
0=no use at the 
time of 
recruitment in 
the study and 
over the 
previous 4 
weeks 
1=Yes  
Age at first use of cannabis 0=started at age 16 
years or older 
1=started at 
age 15 
years or 
younger 
 
Lifetime frequency of use 0=never used 1=used less 
than daily 
2=used daily 
Money spent weekly on 
cannabis 
0=never used or 
spent 20 EURO 
or less per week 
1= spent more 
than 20 
EURO 
per week 
 
Type of cannabis used1 0= never used 1= types 
with 
THC<10% 
2= types with 
THC=>10% 
 
1Explanatory note: The potency variable was defined by a cut off of 10% of the THC concentration 
expected in the different varieties of cannabis in each catchment area, based on government and 
national data examined by the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) 
(European Monitoring Centre for Drugs and Drug Addiction, 2013, Di Forti et al., 2019). 
Cannabis varieties classified as low-potency (THC<10%) were: hash/resin from UK and Italy, imported 
herbal cannabis from UK, Italy, Spain and France, Brazilian marijuana and hash and the Dutch 
Geimporteerde Wiet.  
Cannabis varieties classified as high-potency (THC>10%) were: UK home-grown skunk/sensimilla UK 
Super Skunk, Italian home-grown skunk/sensimilla, Italian Super Skunk, the Dutch Nederwiet, 
Nederhasj and geimporteerde hasj, the Spanish and French Hashish (from Morocco), Spanish home-
grown sensimilla, French home-grown skunk/sensimilla/super-skunk and Brazilian skunk.
 
 
Supplementary table S3. Prevalence of CAPE psychotic experiences in population controls 
 
 
 
 
 
 
CAPE ITEM 
Item 
no. 
Factor 
Valid frequency 
Total sample 
Do you ever feel as if people seem to drop hints about you or say things with a double 
meaning? 
2 POS 50.9% (629) 
Do you ever feel as if things in magazines or on TV were written especially for you? 5 POS 17.6% (217) 
Do you ever feel as if some people are not what they seem to be? 6 POS 74.7% (923) 
Do you ever feel as if you are being persecuted in some way? 7 POS 18.9% (233) 
Do you ever feel as if there is a conspiracy against you? 10 POS 12.4% (153) 
Do you ever feel as if you are destined to be someone very important? 11 POS 30.6% (378) 
Do you ever feel that you are a very special or unusual person? 13 POS 35.5% (438) 
Do you ever think that people can communicate telepathically? 15 POS 25.6% (316) 
Do you ever feel as if electrical devices such as computers can influence the way you think? 17 POS 11.2% (138) 
Do you belief in the power of witchcraft, voodoo or the occult? 20 POS 27.3% (337) 
Do you ever feel that people look at you oddly because of your appearance? 22 POS 34.2% (422) 
Do you ever feel as if the thoughts in your head are being taken away from you? 24 POS 3.9% (48) 
Do you ever feel as if the thoughts in your head are not your own? 26 POS 7.3% (90) 
Have your thoughts ever been so vivid that you were worried other people would hear them? 28 POS 10.6% (131) 
Do you ever hear your own thoughts being echoed back to you? 30 POS 9.1% (112) 
Do you ever feel as if you are under the control of some force or power other than yourself? 31 POS 5.3% (66) 
Do you ever hear voices when you are alone? 33 POS 6.8% (84) 
Do you ever hear voices talking to each other when you are alone? 34 POS 1.9% (23) 
Do you ever feel that you are not a very animated person? 3 NEG 44.8% (553) 
Do you ever feel that you are not much of a talker when you are conversing with other people? 4 NEG 51.8% (640) 
Do you ever feel that you experience few or no emotions at important events? 8 NEG 38.1% (470) 
Do you ever feel that you have no interest to be with other people? 16 NEG 50.2% (620) 
Do you ever feel that you are lacking in motivation to do things? 18 NEG 67.2% (830) 
Do you ever feel that you are lacking in energy? 21 NEG 70.9% (876) 
Do you ever feel that your mind is empty? 23 NEG 24.6% (304) 
Do you ever feel that you are spending all your days doing nothing? 25 NEG 42.6% (526) 
Do you ever feel that your feelings are lacking in intensity? 27 NEG 26.2% (323) 
Do you ever feel that you are lacking in spontaneity? 29 NEG 39.6% (489) 
Do you ever feel that your emotions are blunted? 32 NEG 31% (383) 
Do you ever feel that you are neglecting your appearance or personal hygiene? 35 NEG 27.3% (337) 
Do you ever feel that you can never get things done? 36 NEG 55.1% (680) 
Do you ever feel that you have only few hobbies or interests? 37 NEG 36.4% (450) 
Do you ever feel sad? 1 DEP 93.7% (1,157) 
Do you ever feel pessimistic about everything? 9             DEP 48.8% (603) 
Do you ever feel as if there is no future for you? 12 DEP 27.5% (340) 
Do you ever feel as if you do not want to live anymore? 14 DEP 24.9% (308) 
Do you ever cry about nothing? 19 DEP 34.9% (431) 
Do you ever feel guilty? 38 DEP 73.4% (907) 
Do you ever feel like a failure? 39 DEP 48.1% (594) 
Do you ever feel tense? 40 DEP 81.2% (1,003) 
 
 
 
Supplementary Figure S1 
Path diagrams of the five psychotic experiences’ models 
  
 
Model A 
 
   
Model B 
 
Model C 
 
Model D 
 
 
 
Model E 
 
  
     
Explanatory note: (ሕ) Observed symptoms (CAPE items); (Ö) Unobserved variables (latent 
factors); () item loading on latent factors; () item error variance. CAPE item numbers are 
showed in Tables S1; for simplicity, only three items for each latent factor are presented in the 
diagrams. 
Explanatory note:  Model A: unidimensional model with one unique general factor; Model B: 
multidimensional model with three uncorrelated specific factors; Model C: multidimensional model 
with three correlated specific factors; Model D: bifactor model with one general factor and three 
uncorrelated specific factors; Model E: hierarchical model with three correlated first-order specific 
factors and one general second-order factor. 
As showed in the main text and in Table 1, the bifactor model for the CAPE (Model D) best 
reflected the dimensional structure of psychosis in population controls when compared with the 
other models. This is consistent with our previous findings on the bifactor model for the OPCRIT in 
patients (Quattrone et al., 2019). The bifactor model allows examining the variance due to each 
dimension whilst partitioning out the variance due to the common item effect of the whole 
symptomatology. Thus, in this study, we performed the best possible evaluation of the impact of 
cannabis use on specific subsets of psychotic symptoms or experiences in patients and controls. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Supplementary Table S4. Model fit statistics of unidimensional, multidimensional, bifactor, 
second-order models for psychotic experiences and for psychotic symptoms 
 
CAPE (CONTROLS)  
 Full information fit statisticsa 
 LL AIC BIC SABIC 
A - Unidimensional Model -23638 47397 47715 47524 
B - Multidimensional Model (five uncorrelated factors) -23844 47808 48126 47936 
C - Multidimensional Model (five correlated factors) -23341 46808 47142 46942 
D - Bifactor Model (one general factor and five 
specific uncorrelated factors) 
-23139 46458 46935 46649 
E - Hierarchical Model (five first-order specific correlated 
factors and one second order general factor) -23341 46807 47135 46938 
 
OPCRIT (PATIENTS) (Quattrone et al., 2019) 
 Full information fit statisticsa 
 LL AIC BIC SABIC 
A - Unidimensional Model -29965 60126 60618 60306 
B - Multidimensional Model (five uncorrelated factors) -28070 56335 56826 56515 
C - Multidimensional Model (five correlated factors) -27894 56004 56546 56202 
D - Bifactor Model (one general factor and five 
specific uncorrelated factors) 
-27597 55489 56226 55759 
E - Hierarchical Model (five first-order specific correlated 
factors and one second order general factor) -27995 56197 56713 56386 
 
LL, log-likelihood; AIC, Akaike Information Criterion; BIC, Bayesian Information Criterion; SABIC 
Sample-size Adjusted Bayesian Information Criterion 
A difference of 10 in AIC, BIC and SABIC is considered important. Lower values indicate a statistically 
better model fit (best values across models are indicated in bold). 
 
 
 
Supplementary Table S5. Prevalence of OPCRIT symptoms in patients (Quattrone et al., 2019) 
OPCRIT ITEM 
Item 
no. 
Factor 
Valid frequency 
 
Persecutory Delusions 54 POS 71.6% (794) 
Well organised delusions 55 POS 41.6% (458) 
Delusions of influence 58 POS 24.1% (267) 
Bizarre Delusions 59 POS 23.3% (259) 
Widespread Delusions 60 POS 42.4% (437) 
Delusions of passivity 61 POS 15.2% (168) 
Primary delusional perception 62 POS 26.2% (286) 
Other primary delusions 63 POS 19.4% (213) 
Delusions & hallucinations last for one week 64 POS 47.9% (495) 
Persecutory delusions & hallucinations 65 POS 30.1% (311) 
Thought insertion 66 POS 16.4% (180) 
Thought broadcast 68 POS 15.5% (171) 
Third person auditory hallucinations 73 POS 29.3% (322) 
Running commentary voices 74 POS 24.1% (266) 
Abusive/accusatory/persecutory voices 75 POS 31.8% (329) 
Other (non-affective) auditory hallucinations 76 POS 23.3% (264) 
Non-affective hallucination in any modality 77 POS 26.7% (294) 
 
 
Negative formal thought disorder 29 NEG 19% (209) 
Restricted affect 32 NEG 36.4% (404) 
Blunted affect 33 NEG 21.9% (243) 
Bizarre behaviour 17 DIS 44.9% (496) 
Speech difficult to understand 26 DIS 20.9% (230) 
Incoherent 27 DIS 13% (13) 
Positive formal thought disorder 28 DIS 24.3% (268) 
Inappropriate affect 34 DIS 19.6% (216) 
Excessive activity 19 MAN 25.5% (283) 
Reckless activity 20 MAN 21% (233) 
Distractibility 21 MAN 47.4% (521) 
Reduced need for sleep 22 MAN 30.8% (340) 
Agitated activity 23 MAN 41.3% (457) 
Pressured speech 30 MAN 23% (255) 
Thoughts racing 31 MAN 33% (365) 
Elevated mood 35 MAN 20.6% (229) 
Irritable mood 36 MAN 47.7% (529) 
Increased self esteem 56 MAN 24.1% (267) 
Grandiose Delusions 57 MAN 23.3% (259) 
Slowed activity 24 DEP 23.6% (261) 
Loss of energy/tiredness 25 DEP 40.1% (444) 
Dysphoria 37 DEP 48.7% (540) 
Loss of pleasure 39 DEP 43.2% (477) 
Poor concentration 41 DEP 61% (676) 
Excessive self-reproach 42 DEP 25.8% (286) 
Suicidal ideation 43 DEP 34.2% (380) 
Initial insomnia 44 DEP 52.4% (576) 
Middle insomnia (broken sleep) 45 DEP 38.4% (423) 
Early morning waking 46 DEP 24.9% (274) 
Excessive sleep 47 DEP 15.2% (168) 
Poor appetite 48 DEP 37% (407) 
Weight Loss 49 DEP 29.3% (315) 
 
Supplementary Table S6.1. Symptom dimensions in patients by frequency of use and potency of cannabisa 
Model Lifetime frequency of use 
B (95% CI) 
Potency of cannabis 
B (95% CI) 
Less than daily 
(v. never used) 
Daily 
(v. never used) 
low potency 
(v. no use) 
high potency 
(v. no use) 
Positive symptom 
dimension 
0.1 
(-0.21 to 0.22) 
0.23** 
(0.07 to 0.39) 
0.09 
(-0.12 to 0.28) 
0.22** 
(0.02 to 0.29) 
Negative symptom 
dimension 
-0.07 
(-0.29 to 0.15) 
-0.09 
(-0.26 to 0.09) 
-0.24** 
(-0.41 to -0.06) 
-0.2* 
(-0.39 to -0.02) 
Depressive symptom 
dimension 
-0.12 
(-0.31 to 0.06) 
-0.1 
(-0.24 to 0.04) 
-0.13 
(-0.28 to 0.03) 
-0.13 
(-0.29 to 0.03) 
Disorganization symptom 
dimension 
0.26* 
(0.05 to 0.47) 
0.11 
(-0.04 to 0.27) 
-0.02 
(-0.19 to 0.15) 
0.13 
(-0.04 to 0.32) 
Manic symptom 
dimension 
0.02 
(-0.17 to 0.22) 
0.13 
(-0.02 to 0.28) 
0.23** 
(0.06 to 0.39) 
0.27** 
(0.1 to 0.44) 
General 
Psychosis factor 
0.17* 
(0.01 to 0.33) 
0.12* 
(0.01 to 0.25) 
0.06 
(-0.07 to 0.19) 
0.02 
 (-0.12 to 0.17) 
 
aAll models were adjusted for age, sex, ethnicity, current use of other recreational/illicit substances, and diagnosis. Models were random-intercept models that 
included two random effects to allow symptomatology to vary across countries and across sites within countries but assumed that individual-level exposure to 
cannabis had a fixed effect across the entire sample. 
Significance: * p < 0.05, ** p < 0.01, *** p < 0.001; associations that hold after Benjamini-Hochberg procedure are showed in bold. 
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Supplementary Table S6.2. Psychotic experience dimensions in controls by frequency of use and potency of cannabisa 
Model Lifetime frequency of use 
B (95% CI) 
Potency of cannabis 
B (95% CI) 
Less than daily 
(v. never used) 
Daily use 
(v. rare and never use) 
Low Potency 
v. no use 
High potency 
v. no use 
Positive psychotic 
experience dimension 
0.04 
(-0.08 to 0.16) 
0.17 
(-0.05 to 0.38) 
0.08 
(-0.06 to 0.22) 
0.03 
(-0.13 to 0.19) 
Negative experience 
dimension 
0.11 
(-0.02 to 0.24) 
0.14 
(-0.09 to 0.38) 
0.09 
(-0.05 to 0.24)  
0.12 
(-0.05 to 0.29)  
Depressive 
experience dimension 
0.08 
(-0.05 to 0.2) 
0.17 
(-0.08 to 0.4) 
0.08 
(-0.07 to 0.23) 
0.05 
(-0.11 to 0.22) 
General psychotic 
experience factor 
0.03 
(-0.1 to 0.16) 
0.13 
(-0.11 to 0.37) 
0.08 
(-0.07 to 0.23) 
-0.02 
(-0.19 to 0.15) 
 
aAll models were adjusted for age, sex, ethnicity, current use of other recreational/illicit substances. Models were random-intercept models that included two 
random effects to allow symptomatology to vary across countries and across sites within countries but assumed that individual-level exposure to cannabis had 
a fixed effect across the entire sample. 
Significance: * p < 0.05, ** p < 0.01, *** p < 0.001 
 
 
 
 
 
 
 
 
 
 
 
 
 
Supplementary Figure S2. Symptom dimensions by frequency of use and potency of cannabis  
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